Toggle light / dark theme

Brain-inspired nanopore device uses current-induced heating for memory operations

Some researchers are leaning into biology for inspiration in computing. In particular, neuromorphic computing offers a brain-inspired approach to hardware that replaces traditional binary processing with systems that function more like neurons and synapses. Now, a new study, published in Nature Communications, describes an innovative design for a fluidic memristor that uses its own self-heating mechanism to induce a history-dependent memory effect.

So far, most memristor (memory resistor) devices have used solid materials with electrons or holes functioning as charge carriers. But fluidic memristors instead take advantage of the movement of ions in liquids, which more closely mimics biological signaling, like that which occurs in the brain. However, existing fluidic memristors can be difficult to fabricate and offer a limited range of memory behaviors. The authors of the new study came up with a way to overcome some of these limitations by using temperature fluctuations while also making the device more “brain-like.”

They write, The exploration of additional memristive mechanisms may be beneficial. In conventional integrated circuits, localized heating is generally regarded as an unnecessary and even harmful side effect. However, in biological neural systems, thermal signals are closely linked to essential life processes. They significantly affect neuronal functions, including ion channel activation, action potential conduction speed, and firing patterns.

Neurologic Diagnoses Before and After Traumatic Brain InjuryA Retrospective Cohort Study of Older Veterans

Background and ObjectivesTraumatic brain injury (TBI) during mid-to-late life is associated with increased risk of stroke, Parkinson disease (PD), epilepsy, and dementia. These conditions may also predispose to TBI. Thus, we investigated the incidence of…

Implant helps paralyzed man to feed himself and drink from a cup

A neuroprosthetic system has helped a man with paralysis move his hand and feel touch again following a spinal cord injury, reports research published in Nature Medicine. Some of the system’s benefits continued even when the device was turned off, suggesting that it may support longer-term recovery as well as help movement in real time.

Spinal cord injury is a leading cause of paralysis, and more than half of cases involve tetraplegia, in which movement of the arms and legs is affected. Complete spinal cord injuries, in which there is no voluntary movement or feeling below the level of the injury, are particularly difficult to treat. Previous brain–computer interface systems have helped restore some movement but have not yet restored a sense of touch or supported longer-term recovery.

Chad Bouton and colleagues developed a “double neural bypass” system that reads brain signals linked to a person’s intention to move. It then uses these signals to help control a person’s own hand by delivering targeted stimulation to the spinal cord and the part of the brain involved in touch, the primary somatosensory cortex.

Structural shifts and constraints in animalbased neuroscience

Animal models have long been central to neuroscience, providing direct experimental access to neural processes underlying perception, action, cognition, and disease. Over the past century, work in non-human primates (NHPs), rodents, and other species has established key principles of neural organization and behavior and has supported much of translational neuroscience. However, the institutional and material conditions that sustain animal-based research are now changing in fundamental ways. Ethical and regulatory requirements have intensified, costs and approval timelines have increased, and global supply chains, particularly for NHPs, have become fragile. In parallel, advances in human neuroscience, stem-cell-derived systems, and computational approaches have matured to the point that they challenge the historical reliance on animals for many classes of questions. These forces are not eliminating animal research, but they are reshaping the conditions under which it remains feasible, competitive, and scientifically justified. In this Perspective, we examine how these converging pressures are reconfiguring animal-based neuroscience. We review long-term trends in animal use and accessibility, highlighting species-specific constraints and emerging geopolitical asymmetries. We then analyze the growing role of alternative and complementary platforms, including human brain organoids, genetically engineered rodents, small primates, and ‘human-centric’ neurophysiological and imaging approaches, emphasizing both their strengths and limitations. Finally, we discuss the implications of this diversification for research planning, training, and scientific organization. We argue that the future of neuroscience will be defined not by the disappearance of animal models, but by their integration into hybrid experimental frameworks that preserve mechanistic rigor while adapting to evolving scientific and societal constraints.

Keywords: animal models; neuroscience methodology; alternative experimental platforms; translational validity; research ethics and regulation.

Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial

This multicenter, randomized, double-blind, placebo-controlled, phase 2 trial of ceperognastat in participants with early symptomatic AD was conducted at 72 centers in Australia, Canada, Japan, Poland, and the US from September 2021 to July 2025. The study adhered to the ethical principles outlined in the Declaration of Helsinki20 and other international guidelines. All participants provided written, informed consent before any study-related procedures. The study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.21 The protocol was approved by an ethics committee at each participating center, and unblinded safety data were reviewed approximately every 3 months by an independent unblinded external data and safety monitoring committee. Participants were compensated for study participation. The study protocol and statistical analysis plan are provided in Supplements 1 and 2, respectively.

Eligible participants were aged 60 to 85 years and had a Mini-Mental State Examination (MMSE) score of 22 to 30, Clinical Dementia Rating Scale (CDR) Global Score of 0.5 or 1 with a memory box score greater than or equal to 0.5, elevated plasma level of tau phosphorylated at residue 217 (p-tau217), and evidence of elevated brain tau levels by flortaucipir F18 positron emission tomography (PET) scan at the time of screening. Demographic information, including race and ethnicity, was collected to allow for characterization of potential differences in treatment effects by demographic characteristic. Race and ethnicity were self-reported by participants based on fixed categories. All study participants and study staff were blinded to treatment assignment during the treatment phase.

Blood Test Helps PCPs Diagnose AD With Specialist-Level Accuracy

LONDON — Blood-based biomarker (BBM) testing may enable primary care physicians (PCPs) to diagnose Alzheimer’s disease (AD) as accurately as dementia specialists, potentially expanding access to accurate diagnosis beyond memory clinics, new research suggests.

In a prospective study of more than 1,300 patients, PCPs achieved 93% diagnostic accuracy after reviewing BBM results, which was comparable to the 94% accuracy of dementia specialists. The test also changed clinicians’ diagnoses and management plans in a substantial proportion of cases.

“By equipping primary care practitioners with blood test results, we see that they’re as accurate as dementia experts in definitely ruling out [AD],” study investigator Sebastian Palmqvist, MD, PhD, senior consultant neurologist and associate professor, Lund University, Lund, Sweden, told Medscape Medical News.

Sugar-Coated Nanoparticles Shrink Deadly Brain Tumors in Mice

Cancers don’t come much worse than the brain cancer glioblastoma, and it is notoriously difficult to treat. Even with surgery, radiation, and chemotherapy, fewer than 30 percent of patients are alive two years after diagnosis.

Scientists are busy hunting for treatment approaches that can improve those survival rates, and a team from Oregon State University has now found a potential new angle for attacking these tumors: sugar-coated nanoparticles.

As detailed in a mouse study published in the Journal of Controlled Release, the sugar ‘disguise’ used by the nanoparticles helps them cross the blood-brain barrier to the site of cancer, while also directly targeting glioblastoma and avoiding measurable toxicity in major organs.

/* */